US 10980901

US Patent 10980901, titled "Treatment of PMSA expressing cancers," was issued to European Atomic Energy Community Euratom and Universitaet Heidelberg on April 20, 2021, from an application filed on December 15, 2016. The inventors listed are Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Uwe Haberkorn, Frederik Giesel, and Clemens Kratochwil.

Abstract:
The patent describes a method for treating cancers that express Prostate Specific Membrane Antigen (PSMA). This method involves administering an effective amount of one or more Ac-225-radiopharmaceuticals to a patient in need. The effective amount can be administered either as a dosage ranging from 25 kBq to 400 kBq per kilogram of the patient's body weight, or as a single, fixed dose (unitary dosage) ranging from 3 MBq to 30 MBq.

Plain-Language Overview of Independent Claim 1:
Independent Claim 1 outlines a medical method for treating cancers that exhibit Prostate Specific Membrane Antigen (PSMA) on their cells. The method requires administering a therapeutically active quantity of one or more Ac-225-radiopharmaceuticals to a patient. These radiopharmaceuticals are characterized by Actinium-225 (Ac-225) being chemically bound (chelated) to a specific targeting molecule. This targeting molecule can be one of five described chemical formulas (A, B, C, D, or E), which include various chemical groups and chelating agents (such as DOTA or HBED-CC) or, for Formula E, a PSMA minibody or antibody. The amount of the Ac-225-radiopharmaceutical given to the patient is crucial: it must be an "effective amount," defined either as a dosage between 25 kBq and 400 kBq per kilogram of the patient's body weight, or as a single, consistent dose between 3 MBq and 30 MBq per administration.

CAFC 2026 Dockets:
As of April 26, 2026, no specific dockets concerning US patent 10980901 were found in the CAFC 2026 dockets.